Researchers from Children’s Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform, which can be used to develop cancer treatments by either directly modifying immune cells or by creating proteins that help immune cells locate cancer cells. The findings were published today by the journal Nature Biotechnology.
Medacta to Feature GMK SpheriKA and Innovative Personalized Solutions at AAOS 2024 – Biotech Investments
Medacta Group SA / Key word(s): Miscellaneous Medacta to Feature GMK SpheriKA and Innovative Personalized Solutions at AAOS 2024 12.02.2024 / 19:00 CET/CEST MEDIA RELEASE